174 related articles for article (PubMed ID: 27351137)
1. Heterogeneous polymer composite nanoparticles loaded in situ gel for controlled release intra-vaginal therapy of genital herpes.
Ramyadevi D; Rajan KS; Vedhahari BN; Ruckmani K; Subramanian N
Colloids Surf B Biointerfaces; 2016 Oct; 146():260-70. PubMed ID: 27351137
[TBL] [Abstract][Full Text] [Related]
2. Dual sustained release delivery system for multiple route therapy of an antiviral drug.
Ramyadevi D; Sandhya P
Drug Deliv; 2014 Jun; 21(4):276-92. PubMed ID: 24134619
[TBL] [Abstract][Full Text] [Related]
3. Preparation and evaluation of novel in situ gels containing acyclovir for the treatment of oral herpes simplex virus infections.
Chaudhary B; Verma S
ScientificWorldJournal; 2014; 2014():280928. PubMed ID: 24790559
[TBL] [Abstract][Full Text] [Related]
4. Enhanced antiviral activity of Acyclovir loaded into beta-cyclodextrin-poly(4-acryloylmorpholine) conjugate nanoparticles.
Cavalli R; Donalisio M; Civra A; Ferruti P; Ranucci E; Trotta F; Lembo D
J Control Release; 2009 Jul; 137(2):116-22. PubMed ID: 19361545
[TBL] [Abstract][Full Text] [Related]
5. Effect of carrageenan on poloxamer-based in situ gel for vaginal use: Improved in vitro and in vivo sustained-release properties.
Liu Y; Zhu YY; Wei G; Lu WY
Eur J Pharm Sci; 2009 Jun; 37(3-4):306-12. PubMed ID: 19491020
[TBL] [Abstract][Full Text] [Related]
6. Carrageenan-Based Acyclovir Mucoadhesive Vaginal Tablets for Prevention of Genital Herpes.
Pacheco-Quito EM; Ruiz-Caro R; Rubio J; Tamayo A; Veiga MD
Mar Drugs; 2020 May; 18(5):. PubMed ID: 32403219
[TBL] [Abstract][Full Text] [Related]
7. In-vitro release of acyclovir loaded Eudragit RLPO(®) nanoparticles for sustained drug delivery.
Gandhi A; Jana S; Sen KK
Int J Biol Macromol; 2014 Jun; 67():478-82. PubMed ID: 24755259
[TBL] [Abstract][Full Text] [Related]
8. Atazanavir-loaded Eudragit RL 100 nanoparticles to improve oral bioavailability: optimization and in vitro/in vivo appraisal.
Singh G; Pai RS
Drug Deliv; 2016; 23(2):532-9. PubMed ID: 24963752
[TBL] [Abstract][Full Text] [Related]
9. Development and optimisation of mucoadhesive nanoparticles of acyclovir using design of experiments approach.
Kharia AA; Singhai AK
J Microencapsul; 2015; 32(6):521-32. PubMed ID: 26333938
[TBL] [Abstract][Full Text] [Related]
10. Preparation and characterization of bioadhesive controlled-release gels of cidofovir for vaginal delivery.
Tuğcu-Demiröz F; Acartürk F; Özkul A
J Biomater Sci Polym Ed; 2015; 26(17):1237-55. PubMed ID: 26300445
[TBL] [Abstract][Full Text] [Related]
11. Pseudoboehmite as a drug delivery system for acyclovir.
Peres RM; Sousa JML; de Oliveira MO; Rossi MV; de Oliveira RR; de Lima NB; Bernussi A; Warzywoda J; Sarmento B; Munhoz AH
Sci Rep; 2021 Jul; 11(1):15448. PubMed ID: 34326377
[TBL] [Abstract][Full Text] [Related]
12. Influence of a niosomal formulation on the oral bioavailability of acyclovir in rabbits.
Attia IA; El-Gizawy SA; Fouda MA; Donia AM
AAPS PharmSciTech; 2007 Dec; 8(4):E106. PubMed ID: 18181527
[TBL] [Abstract][Full Text] [Related]
13. In-vitro/in-vivo characterization of trans-resveratrol-loaded nanoparticulate drug delivery system for oral administration.
Singh G; Pai RS
J Pharm Pharmacol; 2014 Aug; 66(8):1062-76. PubMed ID: 24779896
[TBL] [Abstract][Full Text] [Related]
14. Galactose decorated PLGA nanoparticles for hepatic delivery of acyclovir.
Gupta S; Agarwal A; Gupta NK; Saraogi G; Agrawal H; Agrawal GP
Drug Dev Ind Pharm; 2013 Dec; 39(12):1866-73. PubMed ID: 22397550
[TBL] [Abstract][Full Text] [Related]
15. [Isolation of acyclovir-resistant strains of herpes simplex virus from clinical material].
L'vov ND; Andronova VL; Leont'eva NA; Galegov GA
Vopr Virusol; 1999; 44(6):247-9. PubMed ID: 10665057
[TBL] [Abstract][Full Text] [Related]
16. Enhanced oral bioavailability of acyclovir by inclusion complex using hydroxypropyl-β-cyclodextrin.
Nair AB; Attimarad M; Al-Dhubiab BE; Wadhwa J; Harsha S; Ahmed M
Drug Deliv; 2014 Nov; 21(7):540-7. PubMed ID: 24215288
[TBL] [Abstract][Full Text] [Related]
17. Development and characterization of sponge-like acyclovir ocular minitablets.
Refai H; Tag R
Drug Deliv; 2011 Jan; 18(1):38-45. PubMed ID: 20804440
[TBL] [Abstract][Full Text] [Related]
18. Acyclovir treatment of experimental genital herpes simplex virus infections.
Kern ER
Am J Med; 1982 Jul; 73(1A):100-8. PubMed ID: 6285699
[TBL] [Abstract][Full Text] [Related]
19. Curcumin-polymeric nanoparticles against colon-26 tumor-bearing mice: cytotoxicity, pharmacokinetic and anticancer efficacy studies.
Chaurasia S; Chaubey P; Patel RR; Kumar N; Mishra B
Drug Dev Ind Pharm; 2016; 42(5):694-700. PubMed ID: 26165247
[TBL] [Abstract][Full Text] [Related]
20. Ocular tolerability and in vivo bioavailability of poly(ethylene glycol) (PEG)-coated polyethyl-2-cyanoacrylate nanosphere-encapsulated acyclovir.
Fresta M; Fontana G; Bucolo C; Cavallaro G; Giammona G; Puglisi G
J Pharm Sci; 2001 Mar; 90(3):288-97. PubMed ID: 11170022
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
